Skip to main content
. 2020 Feb 19;10:2986. doi: 10.1038/s41598-020-59818-2

Figure 6.

Figure 6

(A) Evaluation of the binding activity of the truncated mutants of HER2 ECD dI, HER2 ECD dI-1/2II, HER2 ECD dI-1/2III and HER2 ECD dI-III with GB235 as determined by ELISA. (B) Binding ability of chimeric HER2I-III-HER3IV and HER3I-III-HER2IV with GB235 as evaluated by ELISA. (C) The cross-reactivity of GB235 toward mouse, rat or human HER2 was evaluated by ELISA. (D) Binding activity of human HER2 ECD point mutants (D362N, Q374H and H456N) to GB235 as determined by ELISA. The data are expressed as the mean ± SEM of three independent experiments.